Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood

Blood

Volumn 119, Issue 25, 2012, Pages 6175-6176

  Tanaka, Junji ^a   Sugita, Junichi ^a   Shiratori, Souichi ^a   Shigematsu, Akio ^a   Imamura, Masahiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; DASATINIB; EOMESODERMIN; INTERLEUKIN 15; INTERLEUKIN 2; TRANSCRIPTION FACTOR T BET;

CD3+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LETTER; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL CORD BLOOD;

EID: 84862748332     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-416800     Document Type: Letter

References (10)

1. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111(3):1366-1377. (Pubitemid 351213423)
2. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94(1):135-139.
3. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398-1405.
4. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116(5):772-782.
5. Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25(10):1587-1597.
6. Tanaka J, Sugita J, Shiratori S, et al. Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells. Leukemia. 2012;26(5):1149-1152.
7. Tayade C, Fang Y, Black GP, Paffaro VA Jr, Erlebacher A, Croy BA. Differential transcription of Eomes and T-bet during maturation of mouse uterine natural killer cells. J Leukoc Biol. 2005;78(6):1347-1355. (Pubitemid 41779241)
8. Ramirez K, Kee BL. Transcriptional regulation of natural killer cell development. Current Opinion Immunol. 2010;22:193-198.
9. Gordon SM, Chaix J, Rupp LJ, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity. 2012;36(1): 55-67.
10. Montero JC, Seoane S, Ocaña A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17(17):5546-5552.